AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02213419
Drug: Endoscopic ultrasonography-guided double ethanol lavage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes.
Trial: NCT01119599
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02516020
Drug: Global
RxNorm normalized name: Global Lancet 33G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embryos are cultured in single step culture from day 1 to day 5
Trial: NCT02516020
Drug: Origio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
Trial: NCT00553072
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/kg/dose
Trial: NCT00539565
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30
Trial: NCT00539565
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02977065
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO daily for 4weeks
Trial: NCT02977065
Drug: Rosuvastatin 10 mg + CKD-519 100 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO daily for 4weeks
Trial: NCT02405403
Drug: [18F]DPA-714 PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]DPA-714 Positron Emission Tomography
Trial: NCT02225210
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Trial: NCT00670345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients belonging to the control group will receive the same volume of saline infusions.
Trial: NCT05271370
Drug: PRO 140 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro140 SC injection 350 mg
Trial: NCT05271370
Drug: PRO 140 525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 525 mg
Trial: NCT05271370
Drug: PRO 140 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg
Trial: NCT00848731
Drug: nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nitric oxide gas is delivered by facemask
Trial: NCT00564889
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
Trial: NCT06292052
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received neoadjuvant chemotherapy plus immunotherapy
Trial: NCT03942185
Drug: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Trial: NCT03942185
Drug: Oral Chinese Herbal Medicine according with syndrome differentiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Trial: NCT03942185
Drug: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Trial: NCT02436473
Drug: Toothpaste containing 250ppm F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental toothpaste containing 250ppm F
Trial: NCT01683656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
Trial: NCT03316820
Drug: K0706
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study treatment with water after an overnight fast
Trial: NCT03316820
Drug: K0706
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study treatment with water after food
Trial: NCT02224690
Drug: GWP42003-P 20 mg/kg/day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Trial: NCT00141219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00732654
Drug: Milk Protein Extract Immunotherapy goal of 4mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Trial: NCT01248455
Drug: (Anti-KIR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Trial: NCT01702467
Drug: GSK2647544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 0.5mg to 50mg of GSK2647544.
Trial: NCT01702467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules.
Trial: NCT01065818
Drug: Fluoro-L-Thymidine
RxNorm normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
Trial: NCT00379041
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03254446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet
Trial: NCT00732654
Drug: Milk Protein Extract Immunotherapy goal of 7mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
Trial: NCT01617083
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antibiotic used to treat infections
Trial: NCT01617083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thickening compound with sugar and flavoring
Trial: NCT01949038
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01949038
Drug: Sublingual placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00950274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
Trial: NCT00146562
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
Trial: NCT00146562
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
Trial: NCT00948259
Drug: NP031112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Trial: NCT00948259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Trial: NCT02424734
Drug: Aminoglycoside
RxNorm normalized name: Aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional, will be given as per local standard of care.
Trial: NCT03350373
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of FYU-981 under Fasted and fed conditions in the morning.
Trial: NCT01587391
Drug: Placebo to BI 163538 XX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose per subject as oral solution
Trial: NCT02810548
Drug: Nanohydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic bone graft
Trial: NCT03580668
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B/F/TAF administered in accordance with the approved product monograph
Trial: NCT04006353
Drug: ABT
RxNorm normalized name: Abtrim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg, Intravenous infusion
Trial: NCT00046254
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03981562
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take an oral vitamin D supplement once a day for 6 months.
Trial: NCT03981562
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take a placebo oral tablet once a day for 6 months.
Trial: NCT01614431
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
Trial: NCT01614431
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N acetyl cysteine for cystinosis patients CKD stages 1 to 4
Trial: NCT06402396
Drug: bDMARDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
Trial: NCT00732654
Drug: Milk Powder Immunotherapy goal dose 2000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Trial: NCT01116102
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
Trial: NCT00760968
Drug: TAK-783 and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Trial: NCT00760968
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Trial: NCT00790751
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes orally prior to initiation of sexual activity
Trial: NCT01762163
Drug: Qizhitongluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01762163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03383315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9%
Trial: NCT04535804
Drug: Aspirin/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Trial: NCT03070951
Drug: OBE2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE2109 100mg tablets for oral administration once daily
Trial: NCT03070951
Drug: Placebo to match OBE2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Trial: NCT00732654
Drug: Milk Powder Immunotherapy goal dose 1000mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Trial: NCT02831543
Drug: Motireb 5/100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02831543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04080726
Drug: HIP1601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole
Trial: NCT04080726
Drug: HGP1705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nexium Tab
Trial: NCT04080726
Drug: HIP1601 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT04080726
Drug: HGP1705 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT01335451
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
Trial: NCT01335451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
Trial: NCT02318225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Trial: NCT01747993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1 tablet / day for 6 days)
Trial: NCT01696669
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8.
Trial: NCT00979134
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients start at a dose of 80 mg twice daily, with no washout
Trial: NCT00979134
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose is followed by washout 5-10 days before multiple dose
Trial: NCT03875495
Drug: Temferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically modified autologous HSPCs
Trial: NCT02428062
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 5-10 mcg intravenous bolus
Trial: NCT02428062
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
Trial: NCT02428062
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
Trial: NCT04210986
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Trial: NCT03599609
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg, once daily
Trial: NCT01341496
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
Trial: NCT01341496
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
Trial: NCT00006077
Drug: NS2330
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006077
Drug: Levodopa and Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03935321
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 intrathecal bolus injections, each of 45mg
Trial: NCT00731822
Drug: GW685698/GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW685698/GW642444
Trial: NCT03288038
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03898622
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
Trial: NCT04501250
Drug: Humulin NPH
RxNorm normalized name: Humulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection at a dose of 0.4 IU/kg
Trial: NCT02175121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily for 28 days
Trial: NCT01349907
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Trial: NCT02533141
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
Trial: NCT00432666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00000484
Drug: chlorothiazide
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00739635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment period of 17 weeks placebo
Trial: NCT03507829
Drug: Human insulin isophane, Humulin N (Eli Lilly)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human insulin isophane, Humulin N (Eli Lilly)
Trial: NCT03507829
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
Trial: NCT03113162
Drug: BEAM Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity BEAM for Immunoablation